Search Results - "van Dyck, C H"

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease by Salloway, S, Sperling, R, Gilman, S, Fox, N C, Blennow, K, Raskind, M, Sabbagh, M, Honig, L S, Doody, R, van Dyck, C H, Mulnard, R, Barakos, J, Gregg, K M, Liu, E, Lieberburg, I, Schenk, D, Black, R, Grundman, M

“…Bapineuzumab, a humanized anti-amyloid-beta (Abeta) monoclonal antibody for the potential treatment of Alzheimer disease (AD), was evaluated in a multiple…”
Get full text

A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease by SANO, M, BELL, K. L, GALASKO, D, GALVIN, J. E, THOMAS, R. G, VAN DYCK, C. H, AISEN, P. S

“…Lowering cholesterol is associated with reduced CNS amyloid deposition and increased dietary cholesterol increases amyloid accumulation in animal studies…”
Get full text

Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: two phase 3 studies by Harrington, C, Sawchak, S, Chiang, C, Davies, J, Donovan, C, Saunders, A M, Irizarry, M, Jeter, B, Zvartau-Hind, M, van Dyck, C H, Gold, M

“…Two phase 3 studies evaluated the efficacy and safety of rosiglitazone (RSG), a type 2 diabetes treatment, in an extended release (RSG XR) form as adjunctive…”
Get more information

Growth hormone secretagogue MK-677 : No clinical effect on AD progression in a randomized trial by SEVIGNY, J. J, RYAN, J. M, VAN DYCK, C. H, PENG, Y, LINES, C. R, NESSLY, M. L

“…In animals, insulin-like growth factor-1 (IGF-1) increases clearance of beta-amyloid, a pathologic hallmark of Alzheimer disease (AD), from the CNS. Serum…”
Get full text

A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease by SALLOWAY, S, SPERLING, R, CRANS, G, LIANG, E, QUINN, G, BAIRU, M, PASTRAK, A, CEDARBAUM, J. M, KEREN, R, PORSTEINSSON, A. P, VAN DYCK, C. H, TARIOT, P. N, GILMAN, S, ARNOLD, D, ABUSHAKRA, S, HERNANDEZ, C

“…This randomized, double-blind, placebo-controlled, dose-ranging phase 2 study explored safety, efficacy, and biomarker effects of ELND005 (an oral amyloid…”
Get full text

Increased Striatal Dopamine Transmission in Schizophrenia: Confirmation in a Second Cohort by Abi-Dargham, Anissa, Gil, Roberto, Krystal, John, Baldwin, Ronald M., Seibyl, John P., Bowers, Malcom, van Dyck, Christopher H., Charney, Dennis S., Innis, Robert B., Laruelle, Marc

“…OBJECTIVE: The authors previously observed an increase in striatal dopamine transmission following amphetamine challenge in 15 untreated patients with…”
Get full text

Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer’s Disease by Budd Haeberlein, Samantha, Aisen, P.S., Barkhof, F., Chalkias, S., Chen, T., Cohen, S., Dent, G., Hansson, O., Harrison, K., von Hehn, C., Iwatsubo, T., Mallinckrodt, C., Mummery, C.J., Muralidharan, K.K., Nestorov, I., Nisenbaum, L., Rajagovindan, R., Skordos, L., Tian, Y., van Dyck, C.H., Vellas, B., Wu, S., Zhu, Y., Sandrock, A.

“…Background Alzheimer’s disease is a progressive, irreversible, and fatal disease for which accumulation of amyloid beta is thought to play a key role in…”
Get full text

Reduced brain serotonin transporter availability in major depression as measured by [ 123I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane and single photon emission computed tomography by Malison, Robert T, Price, Lawrence H, Berman, Robert, van Dyck, Christopher H, Pelton, Gregory H, Carpenter, Linda, Sanacora, Gerard, Owens, Michael J, Nemeroff, Charles B, Rajeevan, Nallakandi, Baldwin, Robert M, Seibyl, John P, Innis, Robert B, Charney, Dennis S

“…Background: Prior research has suggested reductions in the density of serotonin transporter (SERT) binding sites in blood platelets and post-mortem brain…”
Get full text

The Alpha-2A-Adrenoceptor Agonist, Guanfacine, Increases Regional Cerebral Blood Flow in Dorsolateral Prefrontal Cortex of Monkeys Performing a Spatial Working Memory Task by Avery, Robert A, Franowicz, Jenna S, Studholme, Colin, van Dyck, Christopher H, Arnsten, Amy F.T

“…Research indicates that norepinephrine enhances the working memory functions of the prefrontal cortex (PFC) through actions at post-synaptic, alpha-2A…”
Get full text

SPECT Imaging of Striatal Dopamine Release after Amphetamine Challenge by Laruelle, Marc, Abi-Dargham, Anissa, van Dyck, Chris H, Rosenblatt, William, Zea-Ponce, Yolanda, Zoghbi, Sami S, Baldwin, Ronald M, Charney, Dennis S, Hoffer, Paul B, Kung, Hank F, Innis, Robert B

“…This study assesses the feasibility of using SPECT to image intrasynaptic dopamine release in human striatum following dextroamphetamine sulfate…”
Get full text

Iodine- 123-β-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients by SEIBYL, J. P, MAREK, K, SHEFF, K, ZOGHBI, S, BALDWIN, R. M, CHARNEY, D. S, VAN DYCK, C. H, INNIS, R. B

“…Iodine-123-beta-carbomethoxy-3 beta-(4-iodophenyltropane) (CIT) has been used as a probe of dopamine transporters in Parkinson's disease patients using SPECT…”
Get full text

Age-related decline in central serotonin transporter availability with [ 123I]β-CIT SPECT by van Dyck, Christopher H, Malison, Robert T, Seibyl, John P, Laruelle, Marc, Klumpp, Heide, Zoghbi, Sami S, Baldwin, Ronald M, Innis, Robert B

“…Postmortem studies have provided limited and conflicting data regarding aging effects on the central serotonin transporter (SERT). The present study…”
Get full text

Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer’s Disease by Cohen, Sharon, van Dyck, C. H., Gee, M., Doherty, T., Kanekiyo, M., Dhadda, S., Li, D., Hersch, S., Irizarry, M., Kramer, L. D.

“…Background Lecanemab is a humanized IgG1 monoclonal antibody binding with high affinity to amyloid-beta protein protofibrils. In phase 3 development, lecanemab…”
Get full text

Elevated Striatal Dopamine Transporters During Acute Cocaine Abstinence as Measured by [123I]β-CIT SPECT by Malison, Robert T., Best, Susan E., van Dyck, Christopher H., McCance, Elinore F., Wallace, Elizabeth A., Laruelle, Marc, Baldwin, R. M., Seibyl, John P., Price, Lawrence H., Kosten, Thomas R., Innis, Robert B.

“…OBJECTIVE: The authors examined whether striatal dopamine transporters were altered in acutely (96 hours or less) abstinent cocaine-abusing subjects, as…”
Get full text

Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab by Mallinckrodt, C., Tian, Y., Aisen, P. S., Barkhof, F., Cohen, S., Dent, G., Hansson, O., Harrison, K., Iwatsubo, T., Mummery, C. J., Muralidharan, K. K., Nestorov, I., Nisenbaum, L., Rajagovindan, R., von Hehn, C., van Dyck, C. H., Vellas, B., Wu, S., Zhu, Y., Sandrock, A., Chen, T., Budd Haeberlein, Samantha

“…Objectives Efficacy and safety results from the EMERGE (NCT02484547) and ENGAGE (NCT02477800) phase 3 studies of aducanumab in early Alzheimer’s disease (AD)…”
Get full text

The AlzMatch Pilot Study - Feasibility of Remote Blood Collection of Plasma Biomarkers for Preclinical Alzheimer’s Disease Trials by Walter, Sarah, Langford, O., Jimenez-Maggiora, G. A., Abdel-Latif, S., Rissman, R. A., Grill, J. D., Karlawish, J., Atri, A., Bruschi, S., Hussen, K., Donohue, M. C., Marshall, G. A., Jicha, G., Racke, M., Turner, R. S., van Dyck, C. H., Venkatesh, V., Yarasheski, K. E., Sperling, R., Cummings, J., Aisen, P. S., Raman, R.

“…Background Advances in plasma biomarkers to detect Alzheimer’s disease (AD) biology allows researchers to improve the efficiency of participant recruitment…”
Get full text

Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease: A Randomized Controlled Trial by Mulnard, Ruth A, Cotman, Carl W, Kawas, Claudia, van Dyck, Christopher H, Sano, Mary, Doody, Rachelle, Koss, Elizabeth, Pfeiffer, Eric, Jin, Shelia, Gamst, Anthony, Grundman, Michael, Thomas, Ronald, Thal, Leon J, for the Alzheimer's Disease Cooperative Study

“…CONTEXT Several reports from small clinical trials have suggested that estrogen replacement therapy may be useful for the treatment of Alzheimer disease (AD)…”
Get full text

Characterization of radioactive metabolites of 5-HT2A receptor pet ligand [18F]altanserin in human and rodent by TAN, P.-Z, BALDWIN, R. M, VAN DYCK, C. H, AL-TIKRITI, M, ROTH, B, KHAN, N, CHARNEY, D. S, INNIS, R. B

“…This study was performed to identify and characterize the radiometabolites of the serotonin 5-HT2A receptor ligand [18F]altanserin in supporting quantification…”
Get full text

Single Photon Emission Computerized Tomography Imaging of Amphetamine-Induced Dopamine Release in Drug-Free Schizophrenic Subjects by Laruelle, Marc, Abi-Dargham, Anissa, Van Dyck, Christopher H., Gil, Roberto, D'Souza, Cyril D., Erdos, Joseph, McCance, Elinore, Rosenblatt, William, Fingado, Christine, Zoghbi, Sami S., Baldwin, Ronald M., Seibyl, John P., Krystal, John H., Charney, Dennis S., Innis, Robert B.

“…The dopamine hypothesis of schizophrenia proposes that hyperactivity of dopaminergic transmission is associated with this illness, but direct observation of…”
Get full text

PET Quantification of 5-HT2A Receptors in the Human Brain: A Constant Infusion Paradigm with [18F]Altanserin by van Dyck, Christopher H, Tan, Ping-Zhong, Baldwin, Ronald M, Amici, Louis A, Garg, Pradeep K, Ng, Chin K, Soufer, Robert, Charney, Dennis S, Innis, Robert B

“…[18F]altanserin has been used to label serotonin 5-HT2A receptors, which are believed to be important in the pathophysiology of schizophrenia and depression…”
Get full text